RedHill Biopharma (RDHL +12.0%) announces encouraging results from a preclinical study assessing protease inhibitor opaganib in an in vitromodel of human lung bronchial tissue. Opaganib completely inhibited SARS-CoV-2 replication.
Opaganib is currently being evaluated in a global Phase 2/3 trial and a U.S. Phase 2 study in severely ill COVID-19 patients with pneumonia.
Opaganib demonstrated the most potent activity compared to all compounds tested, including the positive control, Gilead Sciences’ (GILD -2.4%) remdesivir.
In addition to Opaganib, RedHill’s in-vitro study evaluated the antiviral activity of its Phase-2 stage investigational drug, RHB-107.
A U.S. Phase 2/3 study with RHB-107 in an outpatient setting should launch later this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.